Pharmacokinetic variability, efficacy and tolerability of eslicarbazepine acetate–A national approach to the evaluation of therapeutic drug monitoring data and clinical …

T Svendsen, E Brodtkorb, A Reimers, E Molden… - Epilepsy Research, 2017 - Elsevier
Background Eslicarbazepine acetate (ESL) is a new antiepileptic drug (AED), still
insufficiently studied regarding pharmacokinetic variability, efficacy and tolerability. The …

Adjunctive eslicarbazepine acetate in pediatric patients with focal epilepsy: a systematic review and meta-analysis

S Lattanzi, F Brigo, E Grillo, C Cagnetti, A Verrotti… - CNS drugs, 2018 - Springer
Background In the treatment of pediatric epilepsy, there is a critical demand for effective and
safe therapeutic options to address patients' unmet clinical needs. Eslicarbazepine acetate …

Pharmacokinetics, drug interactions and exposure-response relationship of eslicarbazepine acetate in adult patients with partial-onset seizures: population …

A Falcão, E Fuseau, T Nunes, L Almeida… - CNS drugs, 2012 - Springer
Abstract Background: Eslicarbazepine acetate (Zebenix®) is a voltage-gated sodium
channel blocker approved in 2009 by the European Medicines Agency as adjunctive …

[HTML][HTML] Efficacy and safety of eslicarbazepine acetate as adjunctive therapy for refractory focal-onset seizures in children: a double-blind, randomized, placebo …

F Kirkham, S Auvin, J Moreira, H Gama, AC Falcão… - Epilepsy & Behavior, 2020 - Elsevier
Purpose This was a phase-III, randomized, double-blind, placebo-controlled study aimed to
evaluate efficacy and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy in …

Dibenzazepine agents in epilepsy: how does eslicarbazepine acetate differ?

C Lawthom, J Peltola, R McMurray, E Dodd… - Neurology and …, 2018 - Springer
Abstract Carbamazepine (CBZ), oxcarbazepine (OXC), and eslicarbazepine acetate (ESL)
belong to the dibenzazepine family of antiepileptic drugs and are all thought to primarily act …

Pharmacotherapy of epilepsy: newly approved and developmental agents

LJ Stephen, MJ Brodie - CNS drugs, 2011 - Springer
This article discusses seven newly available antiepileptic drugs (AEDs) and agents in phase
III development. Lacosamide, licensed as an adjunctive treatment for partial-onset seizures …

Pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine at steady state in healthy volunteers

C Elger, M Bialer, A Falcão, M Vaz‐da‐Silva… - …, 2013 - Wiley Online Library
Purpose Investigate the pharmacokinetics of once‐daily (QD; 900 mg) and twice‐daily (BID;
450 mg) regimens of eslicarbazepine acetate (ESL) and BID (450 mg) regimen of …

Targeting pharmacoresistant epilepsy and epileptogenesis with a dual-purpose antiepileptic drug

A Doeser, G Dickhof, M Reitze, M Uebachs, C Schaub… - Brain, 2015 - academic.oup.com
In human epilepsy, pharmacoresistance to antiepileptic drug therapy is a major problem
affecting a substantial fraction of patients. Many of the currently available antiepileptic drugs …

Effect of gender on the pharmacokinetics of eslicarbazepine acetate (BIA 2‐093), a new voltage‐gated sodium channel blocker

A Falcão, J Maia, L Almeida, D Mazur… - … & drug disposition, 2007 - Wiley Online Library
Purpose. To determine the effect of gender on the pharmacokinetics of eslicarbazepine
acetate, a novel voltage‐gated sodium channel blocker in the development for the treatment …

Steady‐state plasma and cerebrospinal fluid pharmacokinetics and tolerability of eslicarbazepine acetate and oxcarbazepine in healthy volunteers

T Nunes, JF Rocha, A Falcão, L Almeida… - …, 2013 - Wiley Online Library
Purpose: To evaluate the pharmacokinetics and tolerability of once‐daily eslicarbazepine
acetate (ESL) and twice‐daily oxcarbazepine (OXC) and their metabolites in cerebrospinal …